GeparSixto

NCT01426880 📎

Regimen

Experimental
Paclitaxel weekly + non-pegylated liposomal doxorubicin weekly + carboplatin AUC 1.5-2 weekly x 18 weeks (+ bevacizumab in TNBC cohort).
Control
Paclitaxel + non-pegylated liposomal doxorubicin + bevacizumab (no carboplatin) x 18 weeks.

Population

HER2-negative (TNBC or HER2+ cohort) stage II-III breast cancer in the German GBG network; analysis here focuses on the TNBC subgroup.

Key finding

GeparSixto TNBC cohort showed carboplatin added to anthracycline/taxane/bevacizumab improved pCR and 3-year DFS. Independent corroboration of CALGB-40603 platinum signal.

Source: PMID 24794243

Timeline

  • Publication: 2014 Jun

Guideline citations

  • NCCN BREAST